ArticleInvestigational new drugs2021

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.

Hiroyasu Kaneda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.